30.15
+0.84%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sinphar Pharmaceutical Co
Its shares trade on Taiwan Stock Exchange under the ticker 1734.TW. It has been listed since 17 October 2000. In the fiscal year to 31 December 2025, it reported revenue of TWD 3.37bn and net income of TWD 365.8m. At that date it held total assets of TWD 6.15bn and shareholders' equity of TWD 3.44bn.
Sinphar Pharmaceutical Co. Ltd. is engaged in the manufacturing, processing and trading of various western medicines, therapeutic drugs, medicated cosmetics, nutriment, health care foods, and cleaning liquid. The company is headquartered in Dongshan, Yilan. The company went IPO on 2000-10-17. The firm is also engaged in the sales of functional food products. The Company’s principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The firm mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 Oct 2000
- Website
- sinphar.com ↗
Leadership
Pay as last reported
- Mr. Chih-Wen LeeChairman of the Board, since 1999
- Mr. Yi-Ta LeeVice Chairman of the Board, Chief Scientific Officer, since 2007
- Mr. Zhanglong ChenGeneral Manager-Marketing Center
- Ms. Yunze LuGeneral Manager-Factory Service Office
- Mr. Chao-Re WangGeneral Manager-Subsidiary
- Mr. Nen-Ying YouGeneral Manager-Mainland China Affairs Office
- Mr. Nen-Yu YouGeneral Manager-Subsidiary
- Mr. Yu-Liang PaiGeneral Manager
- Mr. Fengqin ZhangDeputy General Manager-Marketing Center
- Mr. Chih-Hsiao ChenHead of Finance
- Yimei LouCorporate Governance Officer
- Ms. Jing-Jing TangDeputy Chief Science Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sinphar Pharmaceutical Co Ltd possesses a strong market reputation, backed by several decades of experience in the pharmaceutical industry. The company has a wide range of high-quality products, catering to diverse healthcare needs. This has enabled them to establish a loyal customer base and gain a competitive edge.
- Sinphar Pharmaceutical Co Ltd has well-established research and development capabilities, allowing them to innovate and introduce new drugs and therapies to the market. Their focus on research ensures a continuous pipeline of innovative products, contributing to their growth and success.
- The company has a robust distribution network, allowing them to reach a large customer base efficiently. This widespread distribution infrastructure gives them a competitive advantage and enhances their market reach and penetration.
Weaknesses
- One of the weaknesses of Sinphar Pharmaceutical Co Ltd is its heavy reliance on a specific product or market segment. The company may face challenges if that particular product or market faces a decline or if competition intensifies.
- Another weakness is the potential vulnerability to regulatory changes and compliance requirements. The pharmaceutical industry is heavily regulated, and any changes in regulations can have a significant impact on Sinphar Pharmaceutical Co Ltd's operations and profitability.
Opportunities
- Sinphar Pharmaceutical Co Ltd has the opportunity to expand its market presence globally. They can explore new markets and regions where there is a demand for their products. This expansion strategy would diversify their revenue sources and reduce reliance on a single market.
- The growing demand for healthcare products, particularly in emerging markets, presents a significant growth opportunity for Sinphar Pharmaceutical Co Ltd. By leveraging their expertise and product portfolio, they can tap into this growing market and enhance their market share and profitability.
Threats
- Intense competition within the pharmaceutical industry poses a threat to Sinphar Pharmaceutical Co Ltd. Other companies may introduce similar products or therapies, leading to price wars and potential market share erosion.
- Global economic volatility and fluctuations in currency exchange rates can also pose threats to the company's financial stability and profitability. Changes in economic conditions can affect consumer spending patterns and reduce demand for healthcare products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.